EXAS vs OBIO · rev $2.76B vs rev $198.0K
EXACT Sciences Corporation (EXAS) versus Orchestra BioMed Holdings Inc. (OBIO) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Orchestra BioMed Holdings Inc. (OBIO) is a biotechnology company listed on NASDAQ.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported OBIO revenue for 2026-06-30 was $198.0K. Net income was -$44.4M. Revenue was up 80.0% from 2026-03-31 to 2026-06-30. OBIO currently screens at market cap $231.7M.
EXAS currently screens at market cap $20.03B. OBIO currently screens at market cap $231.7M.
Not investment advice. Open the EXAS and OBIO stock pages for the full models.
Not investment advice.